Clinical outcomes in 2481 unselected real-world patients treated with a polymer-free sirolimus-eluting stent: 3 years results from the NANO multicenter Registry

Abstract Objectives To evaluate the 3-year clinical outcomes of a polymer-free sirolimus-eluting, Nano plus stent for the treatment of coronary artery disease in the NANO multicenter Registry. Background The long-term clinical data evaluating the safety and efficacy of the novel polymer-free sirolim...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yi Dai, Rutao Wang, Fengying Chen, Yaojun Zhang, Yi Liu, He Huang, Ping Yang, Ruining Zhang, Bo Zheng, Chao Gao, Yundai Chen, Ling Tao
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Real-world population Percutaneous coronary interventions Polymer-free drug-eluting stent Target lesion failure Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/7b084df3d73e4d87beadc2a068682945
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7b084df3d73e4d87beadc2a068682945
record_format	dspace
spelling	oai:doaj.org-article:7b084df3d73e4d87beadc2a0686829452021-11-14T12:07:29ZClinical outcomes in 2481 unselected real-world patients treated with a polymer-free sirolimus-eluting stent: 3 years results from the NANO multicenter Registry10.1186/s12872-021-02356-01471-2261https://doaj.org/article/7b084df3d73e4d87beadc2a0686829452021-11-01T00:00:00Zhttps://doi.org/10.1186/s12872-021-02356-0https://doaj.org/toc/1471-2261Abstract Objectives To evaluate the 3-year clinical outcomes of a polymer-free sirolimus-eluting, Nano plus stent for the treatment of coronary artery disease in the NANO multicenter Registry. Background The long-term clinical data evaluating the safety and efficacy of the novel polymer-free sirolimus-eluting Nano plus stent (Lepu Medical, Beijing, China) is limited. Methods The NANO all-comers Registry trial was a prospective, multicenter clinical registry conducted in 26 centers in China between August 2016 and January 2017. A total of 2481 consecutive patients were exclusively treated with the Nano plus stent. The primary clinical endpoint, target lesion failure (TLF, defined as cardiac death, target vessel nonfatal myocardial infarction, and clinically driven target lesion revascularization [CD-TLR]), was analyzed at 3 years. Results At 3 years, 2295 patients (92.5%) were followed. The incidence of TLF was 6.8% (168/2481). The rate of cardiac death was 3.8% (94/2481), target vessel nonfatal myocardial infarction 0.7% (18/2481), and CD-TLR 2.9% (68/2481). The rate of definite/probable stent thrombosis was 0.5% (13/2481). The risk factors of diabetes mellitus, acute myocardial infarction, age, chronic renal failure, in-stent restenosis, chronic total occlusion, and left ventricular ejection fraction < 40% were the independent predictors of 3-year TLF. Conclusions At three years, the rate of TLF was relatively low in patients treated with the polymer-free Nano plus stent. The polymer-free Nano plus stent showed a favorable safety and efficacy profile in real-world patients. Clinical trial registration URL: https://www.clinicaltrials.gov/ . Unique identifier: NCT02929030.Yi DaiRutao WangFengying ChenYaojun ZhangYi LiuHe HuangPing YangRuining ZhangBo ZhengChao GaoYundai ChenLing TaoBMCarticleReal-world populationPercutaneous coronary interventionsPolymer-free drug-eluting stentTarget lesion failureDiseases of the circulatory (Cardiovascular) systemRC666-701ENBMC Cardiovascular Disorders, Vol 21, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Real-world population Percutaneous coronary interventions Polymer-free drug-eluting stent Target lesion failure Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Real-world population Percutaneous coronary interventions Polymer-free drug-eluting stent Target lesion failure Diseases of the circulatory (Cardiovascular) system RC666-701 Yi Dai Rutao Wang Fengying Chen Yaojun Zhang Yi Liu He Huang Ping Yang Ruining Zhang Bo Zheng Chao Gao Yundai Chen Ling Tao Clinical outcomes in 2481 unselected real-world patients treated with a polymer-free sirolimus-eluting stent: 3 years results from the NANO multicenter Registry
description	Abstract Objectives To evaluate the 3-year clinical outcomes of a polymer-free sirolimus-eluting, Nano plus stent for the treatment of coronary artery disease in the NANO multicenter Registry. Background The long-term clinical data evaluating the safety and efficacy of the novel polymer-free sirolimus-eluting Nano plus stent (Lepu Medical, Beijing, China) is limited. Methods The NANO all-comers Registry trial was a prospective, multicenter clinical registry conducted in 26 centers in China between August 2016 and January 2017. A total of 2481 consecutive patients were exclusively treated with the Nano plus stent. The primary clinical endpoint, target lesion failure (TLF, defined as cardiac death, target vessel nonfatal myocardial infarction, and clinically driven target lesion revascularization [CD-TLR]), was analyzed at 3 years. Results At 3 years, 2295 patients (92.5%) were followed. The incidence of TLF was 6.8% (168/2481). The rate of cardiac death was 3.8% (94/2481), target vessel nonfatal myocardial infarction 0.7% (18/2481), and CD-TLR 2.9% (68/2481). The rate of definite/probable stent thrombosis was 0.5% (13/2481). The risk factors of diabetes mellitus, acute myocardial infarction, age, chronic renal failure, in-stent restenosis, chronic total occlusion, and left ventricular ejection fraction < 40% were the independent predictors of 3-year TLF. Conclusions At three years, the rate of TLF was relatively low in patients treated with the polymer-free Nano plus stent. The polymer-free Nano plus stent showed a favorable safety and efficacy profile in real-world patients. Clinical trial registration URL: https://www.clinicaltrials.gov/ . Unique identifier: NCT02929030.
format	article
author	Yi Dai Rutao Wang Fengying Chen Yaojun Zhang Yi Liu He Huang Ping Yang Ruining Zhang Bo Zheng Chao Gao Yundai Chen Ling Tao
author_facet	Yi Dai Rutao Wang Fengying Chen Yaojun Zhang Yi Liu He Huang Ping Yang Ruining Zhang Bo Zheng Chao Gao Yundai Chen Ling Tao
author_sort	Yi Dai
title	Clinical outcomes in 2481 unselected real-world patients treated with a polymer-free sirolimus-eluting stent: 3 years results from the NANO multicenter Registry
title_short	Clinical outcomes in 2481 unselected real-world patients treated with a polymer-free sirolimus-eluting stent: 3 years results from the NANO multicenter Registry
title_full	Clinical outcomes in 2481 unselected real-world patients treated with a polymer-free sirolimus-eluting stent: 3 years results from the NANO multicenter Registry
title_fullStr	Clinical outcomes in 2481 unselected real-world patients treated with a polymer-free sirolimus-eluting stent: 3 years results from the NANO multicenter Registry
title_full_unstemmed	Clinical outcomes in 2481 unselected real-world patients treated with a polymer-free sirolimus-eluting stent: 3 years results from the NANO multicenter Registry
title_sort	clinical outcomes in 2481 unselected real-world patients treated with a polymer-free sirolimus-eluting stent: 3 years results from the nano multicenter registry
publisher	BMC
publishDate	2021
url	https://doaj.org/article/7b084df3d73e4d87beadc2a068682945
work_keys_str_mv	AT yidai clinicaloutcomesin2481unselectedrealworldpatientstreatedwithapolymerfreesirolimuselutingstent3yearsresultsfromthenanomulticenterregistry AT rutaowang clinicaloutcomesin2481unselectedrealworldpatientstreatedwithapolymerfreesirolimuselutingstent3yearsresultsfromthenanomulticenterregistry AT fengyingchen clinicaloutcomesin2481unselectedrealworldpatientstreatedwithapolymerfreesirolimuselutingstent3yearsresultsfromthenanomulticenterregistry AT yaojunzhang clinicaloutcomesin2481unselectedrealworldpatientstreatedwithapolymerfreesirolimuselutingstent3yearsresultsfromthenanomulticenterregistry AT yiliu clinicaloutcomesin2481unselectedrealworldpatientstreatedwithapolymerfreesirolimuselutingstent3yearsresultsfromthenanomulticenterregistry AT hehuang clinicaloutcomesin2481unselectedrealworldpatientstreatedwithapolymerfreesirolimuselutingstent3yearsresultsfromthenanomulticenterregistry AT pingyang clinicaloutcomesin2481unselectedrealworldpatientstreatedwithapolymerfreesirolimuselutingstent3yearsresultsfromthenanomulticenterregistry AT ruiningzhang clinicaloutcomesin2481unselectedrealworldpatientstreatedwithapolymerfreesirolimuselutingstent3yearsresultsfromthenanomulticenterregistry AT bozheng clinicaloutcomesin2481unselectedrealworldpatientstreatedwithapolymerfreesirolimuselutingstent3yearsresultsfromthenanomulticenterregistry AT chaogao clinicaloutcomesin2481unselectedrealworldpatientstreatedwithapolymerfreesirolimuselutingstent3yearsresultsfromthenanomulticenterregistry AT yundaichen clinicaloutcomesin2481unselectedrealworldpatientstreatedwithapolymerfreesirolimuselutingstent3yearsresultsfromthenanomulticenterregistry AT lingtao clinicaloutcomesin2481unselectedrealworldpatientstreatedwithapolymerfreesirolimuselutingstent3yearsresultsfromthenanomulticenterregistry
_version_	1718429411853729792

Clinical outcomes in 2481 unselected real-world patients treated with a polymer-free sirolimus-eluting stent: 3 years results from the NANO multicenter Registry

Ejemplares similares